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Abstract
Since working memory deﬁcits in schizophrenia have been linked to negative symptoms, we tested whether
features of the one could predict the treatment outcome in the other. Speciﬁcally, we hypothesized that working
memory-related functional connectivity at pre-treatment can predict improvement of negative symptoms in
antipsychotic-treated patients. Fourteen antipsychotic-naive patients with ﬁrst-episode schizophrenia were
clinically assessed before and after 7 months of quetiapine monotherapy. At baseline, patients underwent
functional magnetic resonance imaging while performing a verbal n-back task. Spatial independent component
analysis identiﬁed task-modulated brain networks. A linear support vector machine was trained with these
components to discriminate six patients who showed improvement in negative symptoms from eight non-
improvers. Classiﬁcation accuracy and signiﬁcance was estimated by leave-one-out cross-validation and per-
mutation tests, respectively. Two frontoparietal and one default mode network components predicted negative
symptom improvement with a classiﬁcation accuracy of 79% (p=0.003). Discriminating features were found in
the frontoparietal networks but not the default mode network. These preliminary data suggest that functional
patterns at baseline can predict negative symptom treatment–response in schizophrenia. This information may
be used to stratify patients into subgroups thereby facilitating personalized treatment.
Received 14 May 2012 ; Reviewed 14 August 2012 ; Revised 30 August 2012 ; Accepted 17 September 2012 ;
First published online 20 November 2012
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Introduction
In schizophrenia, symptoms are often divided into posi-
tive symptoms, such as hallucinations, delusions and
disorganized thinking, and negative symptoms, such as
anhedonia, alogia and avolition. Negative symptoms are
characterized by an absence of normal behaviour and
share many characteristics with the cognitive deﬁcits also
present in schizophrenia patients. For example, unlike
positive symptoms, negative symptoms and cognitive
impairment : both remain relatively stable over
time (Harvey et al. 2006) ; both respond poorly to anti-
psychotic medication including second generation anti-
psychotics (Lieberman and Stroup, 2011) ; both are good
predictors of functional outcome (Allott et al. 2011) ; both
are associated with dysfunction in similar brain regions
(Williamson, 2007).
Working memory (WM) is often impaired in schizo-
phrenia (Lee and Park, 2005) and has been directly linked
to the presence of negative symptoms (Seamans and
Yang, 2004). While neuroimaging studies have failed to
pinpoint a speciﬁc region of dysfunction relating to ob-
served WM deﬁcits (Glahn et al. 2005), they have con-
sistently shown impaired functional connectivity within
networks activated by WM tasks (Schlosser et al. 2003;
Meda et al. 2009 ; Henseler et al. 2010). Of note is that one
study was able to diﬀerentiate schizophrenia patients
from healthy control subjects with 96% accuracy based
on functional connectivity during an n-back WM task
(Meyer-Lindenberg et al. 2001). These ﬁndings of dys-
connectivity tie in with the notion that schizophrenia is
primarily associated with impairment of functional inte-
gration within brain networks rather than aﬀecting neu-
ronal processing in a single brain area (Stephan et al.
2009).
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In the present study, we employed a multivariate ap-
proach, which allows the detection of subtle large-scale
alterations in network dynamics that have been proposed
to underlie schizophrenia. The strength of using a multi-
variate classiﬁcation approach is exempliﬁed by recent
work showing that spatially distributed information in
brain tissue in schizophrenia patients at baseline
predicted the frequency of psychotic episodes at 6 yr
follow-up (Mourao-Miranda et al. 2012). Although this
multivariate approach is fundamentally data-driven,
the features that are selected to make the classiﬁcation are
driven by theory. Both task-positive and task-negative
networks are implicated in the dysfunctional working
memory processes in schizophrenia (Anticevic et al.
2011). Considering the many similarities between nega-
tive symptoms and cognitive impairment, we hypothe-
sized that the functional networks underlying working
memory at pre-treatment baseline in antipsychotic-naive,
ﬁrst-episode patients would be predictive of negative
symptom improvement after 7 months of atypical anti-
psychotic treatment with quetiapine. This study is partly
motivated by the need for clinical aids in order to guide
treatment choice in the clinic, and also by the need to
better understand the underlying pathophysiology of
symptoms that respond poorly to drug treatment.
Method
Participants
Fourteen antipsychotic-naive, ﬁrst-episode patients (11
male and three female) were clinically assessed and
scanned with magnetic resonance imaging (MRI) at
baseline and clinically reassessed 6.89 (S.D.=0.57) months
after quetiapine drug treatment at clinically eﬃcacious
doses (mean dose=518 mg; S.D.=291 mg). Patients were
recruited as part of a larger prospective study on ﬁrst-
episode schizophrenia. Structural and univariate func-
tional MRI (fMRI) ﬁndings have been reported elsewhere
(Ebdrup et al. 2010, 2011 ; Nejad et al. 2011). A total of 17
patients of whom we had fMRI data at baseline were
followed up after quetiapine treatment at 7 months. Two
were excluded based on poor imaging quality and one
patient was excluded based on missing symptom assess-
ment data.
Inclusion criteria were a diagnosis of schizophrenia, no
prior exposure to antipsychotic medication, aged
18–45 yr, no medical or neurological co-morbidity and no
history of signiﬁcant head injury. MRI scans were with-
out pathology as evaluated by a neuroradiologist.
Diagnoses were based on the schedules for clinical as-
sessment in neuropsychiatry (SCAN), version 2.1 (Wing
et al. 1990). Duration of untreated illness (DUI) was esti-
mated from clinical interviews, records and, where
possible, interviews with relatives. DUI was deﬁned as
the time between onset of unspeciﬁed psychotic symp-
toms to the date of the MRI scan. Psychopathology was
assessed with the positive and negative syndrome scale
(PANSS; Kay et al. 1987) by trained raters. Interviews
were video-recorded for validation purposes. An intra-
class correlation of 0.92 was achieved in a two-way mixed
eﬀect model of 10 random interviews. All participants
were right-handed as assessed by the Edinburgh hand-
edness inventory (Oldﬁeld, 1971). For all participants
parental-socioeconomic status (P-SES) was assessed
(Hansen, 1986). Six patients were prescribed benzodia-
zepine but abstained on the day of MRI scanning. One
patient received SSRI medication (ﬂuoxetine) at the time
of scanning and two patients last received SSRI medi-
cationo16 months prior to study inclusion. Four patients
fulﬁlled lifetime DSM-IV criteria for substance abuse, two
of whom had no history of abuse for the past year and
one had none for the past month. One patient had
smoked cannabis on a few occasions in the month prior to
the MRI scan. Substance dependence was an exclusion
criterion. All subjects had a negative urine screening for
substance intake before the examinations.
The study was conducted in compliance with the
Helsinki II Declaration and approved by the Ethics
Committee of the Capital Region (H-KF-01-78/97). All
participants gave written consent after receiving a writ-
ten and oral description of the study.
Experimental working memory task
We used the verbal n-back task to probe working mem-
ory functional networks. This task has been found to re-
liably activate known working memory areas (Rottschy
et al. 2012) and has been used extensively in schizo-
phrenia research (Glahn et al. 2005). The verbal n-back
task consisted of four conditions : rest ; 0-back; 1-back;
2-back. Participants performed seven blocks of each con-
dition in a pseudo-random order. During the rest con-
dition, a ﬁxation cross was continuously displayed and
subjects lay still with their eyes open. During the n-back
conditions, 15 letters were presented for 0.5 s in the centre
of the screen every 2 s. Participants pressed the response
key ‘yes’ with their right index ﬁnger to every stimulus
that was presented in the previous trial for the 1-back
condition or two trials previously for the 2-back con-
dition. In the 0-back condition, participants were in-
structed to respond ‘yes’ whenever the letter ‘X’
appeared on the screen. On average, each block contained
four targets out of 15 stimuli. Subjects responded to non-
targets by pressing the response key ‘no’ with their right
middle ﬁnger. Participants performed a practice run
outside the scanner.
MRI
MRI was performed using a 3-T Siemens Trio scanner
(Siemens, Germany). A high-resolution anatomical brain
scan was acquired using a 3D T1-weighted sagittal mag-
netization prepared rapid gradient echo (MPRAGE) se-
quence of the whole head (TR=1540 ms; TE=3.92 ms;
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ﬂip angle=9x ; voxel size=1 mm3 ; 192 slices). Echo
planar imaging (EPI) was used to measure blood oxygen
level dependent (BOLD) signal as an index of regional
neural activity (TR=2000 ms; TE=30 ms; ﬂip an-
gle=90x ; FOV=240 mm; voxel size=3.8 mm, isotropic
resolution). Each acquired brain volume consisted of
31 contiguous slices oriented parallel to the anterior
commissure–posterior commissure plane. A total of 477
whole-cerebrum measurements were acquired dur-
ing WM task performance. We also acquired a B0 ﬁeld
map (TR=400 ms; TE1=5.19 ms; TE2=7.65 ms; ﬂip
angle=60x ; distance factor=25%; FOV=240 mm; 31
slices ; slice thickness=3 mm).
fMRI data processing
Pre-processing was conducted with SPM5 (Wellcome
Trust Centre for Neuroimaging, UK). To correct for
scanner gradient nonlinearities, the structural MPRAGE
image was unwarped before being normalized to the
Montreal Neurological Institute (MNI) template using the
VBM5.1 toolbox. The EPI images were unwarped using a
voxel displacement map created from the gradient non-
linearity and acquired B0 ﬁeld maps (Andersson
et al. 2001). Subsequently, the mean EPI image was co-
registered to the MPRAGE image. All EPI images were
then realigned to the mean EPI image. Next, EPI images
were transformed into MNI space (2 mm isotropic resol-
ution) by applying the spatial normalization transform-
ation parameters of the MPRAGE image. Finally, the EPI
images were smoothed with a Gaussian kernel of 8 mm
full-width half-maximum.
Demographic and behavioural data analyses
Statistical analyses were performed with SPSS version 18
software. Paired t tests tested for clinical changes in
PANSS scores from baseline to follow-up. Patients were
grouped according to improvement on the PANSS nega-
tive symptom scale by subtracting patients’ negative
symptom score at follow-up from their baseline score.
Percentage changes were calculated after transforming
the PANSS scores from interval to ratio scale (Obermeier
et al. 2011). We used the traditional threshold of a 20%
reduction in PANSS symptom scores (Mortimer, 2007) to
deﬁne patients as negative symptom improvers.
Mann–Whitney U tests tested for group diﬀerences be-
tween improvers and non-improvers on all PANSS
scores, mean quetiapine dose, DUI, age and handedness
scores. Sex ratio, benzodiazepine prescriptions and P-SES
were analysed for between-group diﬀerences with x2
tests.
For each n-back condition, we calculated the mean re-
action time (RT) and mean signal detection sensitivity, d ’.
RT was measured from the time of stimulus presentation
until the response. The sensitivity measure, d ’, which in-
dicates how well participants are able to respond cor-
rectly to both targets and non-targets, was calculated as
the Z-transform of the hit rate minus the Z-transform of
the false-alarm rate (MacMillan and Creelman, 2005).
Higher values of d ’ denote better WM performance.
A repeated-measures general linear model tested for
group (improvers, non-improvers) and group-by-WM
load interaction eﬀects. WM load (1-back and 2-back) was
a within-subject factor. RT and d ’ were dependent vari-
ables. Signiﬁcance was set at a two-tailed level of 0.05.
fMRI data analysis
The fMRI data analysis proceeded in the following steps :
(1) selection of features : spatial independent component
analysis (ICA) was used to extract temporally coherent
functional networks (i.e. components) from fMRI signals.
Those components that showed the strongest associations
with the task were selected for further analyses ; (2)
classiﬁcation: a linear support vector machine (SVM)
classiﬁer was employed to determine whether the infor-
mation contained in the selected functional networks
distinguished patients who would later go on to improve
in negative symptoms from those who would not ; (3)
visualization: ﬁnally, we visualized the brain areas which
best diﬀerentiated the two groups by use of weight maps.
Selection of features
Spatial ICA for group analysis was run using the Group
ICA of fMRI Toolbox (http://icatb.sourceforge.net, ver-
sion 2.0c). Spatial ICA reduces the functional imaging
data into time-courses and associated spatial maps,
which account for most of the variance in the temporal
data. The brain areas within the resulting spatial maps
share a common pattern in their time series. Those spatial
maps whose temporal patterns show the strongest cor-
relations with onset of task conditions are presumed to
signify task-related networks.
As a ﬁrst step, the dimensionality of the pre-processed
fMRI data from all subjects was reduced by singular
value decomposition to 20 dimensions per subject and
temporally concatenated. Independent components,
a priori set to 20, were then estimated from the aggregate
data using the Infomax algorithm. We estimated 20 in-
dependent components as this number has previously
been shown, in a study using a similar verbal n-back task,
to divide data into meaningful task-related networks
(Gordon et al. 2012). Next, subject-speciﬁc spatial maps of
each component were generated through back recon-
struction of the group components onto subject-speciﬁc
functional data, after which individual component maps
were Z-transformed with voxel values expressing signal
deviation from the group-averaged component (higher
voxel values indicating greater expression of the group
component’s temporal pattern).
Finally, multiple regression of the 1-back and 2-back
WM task parameters against the time series of the group
mean components identiﬁed those components which
were strongest associated with the changes in the task,
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i.e. task-related components representing networks
modulated by WM processing. These components were
then used to train a classiﬁer in distinguishing negative
symptom improvers from non-improvers.
Classiﬁcation
Machine learning classiﬁers attempt to ﬁnd a dividing
plane, given the data, which best separate sets of grouped
data. We used a linear SVM (Cortes and Vapnik, 1995) as
our classiﬁer using LIBSVM version 3.1 software (http://
www.csie.ntu.edu.tw/ycjlin/libsvm). SVMs are well-
suited for multivariate pattern discrimination between
two classes of high dimensional data, i.e. for group
analysis of functional neuroimages. The sequential mini-
mal optimization algorithm, incorporated in LIBSVM,
was used to deﬁne the hyperplane that best separated
data labelled as negative symptom improvers and non-
improvers. The C-parameter, which penalizes for incor-
rect predictions, was ﬁxed at the default setting of 1.
Classiﬁcation accuracy was estimated by leave-one-out
cross-validation. The classiﬁer was trained on all data
labelled as a member of negative symptom improvers or
negative symptom non-improvers. One data set re-
mained unlabelled and was used to test whether the
trained classiﬁer was able to correctly classify it as be-
longing to the ‘improver’ or ‘non-improver’ group. This
procedure was repeated until each subject’s data was left
out of classiﬁer-training and used as a test data set. The
accuracy rate of classiﬁcation was indicative of the per-
centage of times the classiﬁer correctly identiﬁed the un-
labelled data sets. We further calculated sensitivity
(proportion of true positives, i.e. correctly classiﬁed im-
provers) and speciﬁcity (proportion of true negatives, i.e.
correctly classiﬁed non-improvers).
The statistical signiﬁcance of the classiﬁer was tested
by rerunning the leave-one-out procedure on 1000 ran-
dom permutations of the training-set class labelling. The
p-value was thus a non-parametric indication of how of-
ten a classiﬁer trained on a random class labelling could
perform with better leave-one-out accuracy than the
classiﬁer trained on the true labelling of improvers and
non-improvers.
Visualization
When applying SVM, it is possible to obtain voxel values
indicating how important a given voxel is for deﬁning the
dividing hyperplane between two classes. These values,
or classiﬁer weights, can be used to identify brain areas
which make a strong contribution to classiﬁcation. For
this, we constructed reproducible activation volumes
using the procedure outlined in Rasmussen et al. (2011)
employing the NPAIRS split-half resampling technique
(Strother et al. 2002). This method estimates a re-
producible activation map of Z-scores by plotting
the similarity of classiﬁer weights obtained from 200 in-
dependent split-half samples. The resulting volumes
were thresholded at Bonferroni’s corrected p value
of 0.05. The surviving clusters were those which were
reproducibly important for the classiﬁer to draw the
dividing hyperplane between negative symptom im-
provers and non-improvers.
Results
Demographic and behavioural data analyses
Demographic and clinical data are presented in Table 1.
Patients improved signiﬁcantly on the positive symptom
subscale after 7 months of quetiapine treatment (t13=4.0 ;
p=0.002). However, we did not observe any signiﬁcant
improvements from baseline to follow-up on the nega-
tive, general or total PANSS scores (p>0.15 for all).
For the negative symptoms, six patients with positive
diﬀerence scores were grouped as negative symptom
improvers (range 18.75–100% change). Eight patients
displaying negative (n=6; range 6.7–100% change) or
null (n=2) diﬀerence scores were grouped as negative
symptom non-improvers (Table 2). Two of the patients
that we grouped as ‘improvers’ fell just below our pre-
deﬁned threshold at a symptom reduction of 19%,
whereas the rest displayed >25% symptom reduction.
Nevertheless, the large gulf between ‘improvers’ and
‘non-improvers ’ (>19%) indicates that there was a
qualitative clinical diﬀerence between our deﬁned
groups. Handedness, P-SES, mean quetiapine dose, ben-
zodiazepine prescriptions and sex ratio were not signiﬁ-
cantly diﬀerent between improvers and non-improvers
(p>0.2 for all). Negative symptom improvers were sig-
niﬁcantly (U=7.0 ; Z=x2.19 ; p=0.023) younger than
non-improvers, but did not diﬀer in DUI (p=0.34). The
baseline PANSS negative symptom subscale scores dif-
fered signiﬁcantly between the improvers and non-
improvers (U=8.5 ; Z=x2.01 ; p=0.043), otherwise no
signiﬁcant diﬀerences were found on the PANSS total or
other subscales (p>0.28 for all). Finally, improvers and
non-improvers did not show any signiﬁcant between-
group diﬀerences or interactions in d ’ (p>0.70 for all) or
Table 1. Demographic and Positive and Negative Syndrome
Scale (PANSS) assessments at baseline and follow-up for all
study participants
Baseline Follow-up
Mean S.D. Mean S.D.
Age (yr) 26.78 4.99
Edinburgh handedness score 97.61 6.25
Negative PANSS 21.21 6.05 20.71 5.24
Positive PANSS 20.64 3.59 16.21* 3.85
General PANSS 40.64 8.54 39.57 9.49
Total PANSS 82.50 13.89 76.50 17.52
* Signiﬁcant improvement over time.
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RT (p>0.17 for all) on the n-back task. All participants
performed the n-back task to an acceptable standard with
a mean of 90 correct trials out of a possible 105 trials
(S.D.=8.4) in the 2-back condition, ensuring that all
patients were engaged in the task.
ICA and classiﬁcation results
The regression of the group mean components’ time
series on the 1-back and 2-back WM task parameters
identiﬁed a right-lateralized frontoparietal WM network
component (R2=0.367), a default mode network (DMN)
component (R2=0.275) and a bilateral frontoparietal WM
network component (R2=0.187; Fig. 1).
These three network components were used to train
the linear SVM classiﬁer. The classiﬁcation accuracy was
79% (sensitivity=75%; speciﬁcity=83.3%), signiﬁcant at
p=0.003, in spite of the relatively small sample size.
Post hoc classiﬁcation results
A number of confounding variables diﬀered between the
‘improver’ and ‘non-improver’ groups. Therefore,
classiﬁcation was rerun with the data grouped according
to these ‘nuisance’ variables in order to investigate whe-
ther classiﬁcation improved with this relabelling and so
whether these group-diﬀerences were driving our re-
sults.
Since the improvers and non-improvers signiﬁcantly
diﬀered on baseline negative symptom scores (as as-
sessed by the PANSS negative symptom scale), we
trained a linear SVM classiﬁer on high (n=6) vs. low
(n=8) scorers, grouped according to whether they scored
above or below the baseline negative symptom mean
of 21. The classiﬁcation accuracy declined to 43%
(sensitivity=62.5%; speciﬁcity=16.7%), suggesting that
baseline diﬀerence in negative symptom scores did not
inﬂuence our earlier result.
Also, Lysaker et al. (1997) previously reported that
cognitive impairment could predict the stability of nega-
tive symptoms at 6-month follow-up. To test whether in
our study the WM-related network components pre-
dicted the temporal stability of negative symptoms rather
than the direction of symptom change, we grouped pa-
tients according to the same criteria as the Lysaker et al.
study (stable scorers<4 point change<variable scorers).
Six patients were labelled as stable negative symptom
scorers and eight as variable negative symptom scorers.
Rerunning the leave-one-out cross-validation resulted in
a classiﬁcation accuracy of 57.14% (sensitivity=16.7%;
speciﬁcity=87.5%), suggesting that diﬀerences in the
magnitude of negative symptom change between nega-
tive symptom improvers and non-improvers were not
driving our classiﬁcation results.
Finally, we tested whether the signiﬁcant age diﬀer-
ence between the groups was driving the classiﬁcation by
grouping the patients according to whether they scored
above the mean age of 27 yr (n=7) or below (n=7). The
classiﬁcation accuracy dropped to 50% (sensi-
tivity=42.9%; speciﬁcity=57.1%), suggesting that
the age diﬀerence did not inﬂuence the classiﬁcation
accuracy of the negative symptom improvers vs. non-
improvers.
Mapping classiﬁer weights
The reproducible activation map shows the brain regions
which were most reproducibly distinct between the im-
provers and non-improvers (Fig. 2). These regions were
Table 2. Demographic and positive and negative syndrome scale (PANSS) assessments for
negative symptom improvers and non-improvers
Negative symptom
improvers (n=6)
Negative symptom
non-improvers (n=8)
Mean S.D. Mean S.D.
Baseline age (yr) 23.93 3.76 28.92* 4.89
Edinburgh handedness score 98.33 4.08 96.99 7.96
Baseline negative PANSS 24.83 7.55 18.50* 2.78
Baseline positive PANSS 20.33 5.28 20.88 1.96
Baseline general PANSS 39.83 5.91 41.25 10.47
Baseline total PANSS 85.00 15.39 80.63 13.42
Positive PANSS diﬀerencea 4.50 6.12 4.37 2.26
General PANSS diﬀerencea 2.83 6.94 x0.25 10.33
Total PANSS diﬀerencea 12.83 12.04 0.87 15.24
Mean quetiapine dose (mg) 436 290 578 295
Duration of untreated illness (wk) 169 234 317 324
* Signiﬁcant diﬀerence between groups.
a Values reﬂect means of diﬀerence scores (baseline minus follow-up symptom scale scores)
with positive values denoting improvement.
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mainly located within the WM network, including pre-
cuneus, right superior and inferior parietal and right
dorsolateral, ventrolateral and medial prefrontal cortices.
Generally, these regions expressed low values in the
subject component maps, values of which are indicative
of the extent the voxel’s time-course covaries with
the time-course of the network represented in the mean
group component. Low values therefore indicate low
contribution to the variance of the network’s time-course
and thereby suggest that these clusters were not major
nodes of the frontoparietal networks.
Post hoc comparison of features
In order to estimate how important each component was
for diﬀerentiating patients who later improved on nega-
tive symptoms from those who did not, we one-by-one
removed a component from the classiﬁer and repeated
leave-one-out cross-validation (Table 3). Removing the
DMN component did not change the accuracy of the
classiﬁer in discriminating between negative symptom
improvers and non-improvers. Training the classiﬁer
on each component separately revealed that the right-
lateralized WM network component performed best.
Discussion
WM-related functional connectivity patterns at
pre-treatment baseline predicted the improvement in
negative symptoms with an accuracy of 79% in anti-
psychotic-naive schizophrenia patients who were subse-
quently treated with quetiapine. The frontoparietal WM
networks rather than the DMN contained most of the
predictive information regarding the later improvement
in negative symptoms. Moreover, the classiﬁer trained on
the more right-lateralized frontoparietal network com-
ponent performed best of the classiﬁers trained on indi-
vidual components. Accordingly, the reproducibility
activation maps highlighted the right prefrontal and
parietal clusters of the WM components as those brain
regions where the activity pattern contributed most to the
Fig. 1. Independent components of interest maps. Axial slices showing the three components used for classiﬁcation (thresholded at
z-score of 1.7). Red colour map indicates the bilateral frontoparietal component ; green colour map indicates the right-lateralized
frontoparietal component ; blue colour map indicates the default mode network component.
Fig. 2. Reproducible activation maps. 3D brain showing areas which are most informative to the classiﬁer (thresholded at two-tailed
Bonferroni’s corrected p=0.05 ; minimum cluster size of 20 voxels). Colour maps correspond to the respective component – red and
green for the frontoparietal working memory components.
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discrimination between patients who showed subsequent
improvement in negative symptoms from those who did
not. The right-lateralized frontoparietal component also
ﬁtted best with the WM task conditions, suggesting that
the most cognitively-engaged network best predicted the
course of negative symptoms. Critically, our ﬁndings
cannot be attributed to an overt dysfunction of WM since
negative symptom improvers and non-improvers did not
diﬀer in WM performance.
Although the parietal and prefrontal regions generally
constitute key nodes in the WM network (Champod and
Petrides, 2007), most of the identiﬁed clusters in the re-
producibility activation maps did not express strong
connectivity within the frontoparietal networks in either
the negative symptom improving or non-improving
group. In agreement with this observation, a recent study
applying graph theory to analyse resting-state functional
brain connectivity in schizophrenia revealed that it was
particularly the weak connections within network or-
ganization that were altered in schizophrenia patients
(Bassett et al. 2012). Since alterations in these weak con-
nections were found to correlate with cognition, as well
as negative symptom measures, the authors concluded
that dysconnectivity of peripheral rather than central
network nodes might underpin cognitive deﬁcits (Bassett
et al. 2012). Our data suggest that baseline connectivity in
weak connections of the WM network may also deter-
mine which course negative symptoms subsequently take
during antipsychotic treatment.
Regions belonging to the DMN were largely absent in
the reproducibility activation maps. This indicates that
the classiﬁer did not ﬁnd voxels pertaining to the DMN
component important in order to diﬀerentiate improvers
from non-improvers. The lack of distinguishing features
in the DMN is further supported by the post hoc com-
parison of features where removing the DMN component
did not change the accuracy of the classiﬁer. Some
previous ﬁndings (Bluhm et al. 2007; Lui et al. 2009), but
not all (Garrity et al. 2007), have suggested that DMN
connectivity is correlated with negative symptom sever-
ity. Although our ﬁndings do not necessarily conﬂict
with an association between DMN connectivity and
negative symptoms, they do suggest that the DMN con-
tains little predictive value for negative symptom treat-
ment response.
Quetiapine is a second generation antipsychotic with a
complex receptor proﬁle. Its main therapeutic eﬀect on
cognition and negative symptoms, if any, is thought to
stem from its dopamine 2 (D2) and serotonin 2A (5-HT2A)
receptor antagonism, which leads to an overall increase
in dopaminergic activity in the prefrontal cortex (da Silva
Alves et al. 2008). In healthy subjects, pharmacological
modulation of dopaminergic neurotransmission has
produced diﬀerential eﬀects on cognitive performance
and connectivity. The dopamine agonist bromocriptine
increased frontostriatal functional connectivity and im-
proved WM performance in low-WM span subjects but
decreased connectivity and worsened performance in
high-span subjects (Wallace et al. 2011). The diﬀerential
eﬀect of bromocriptine supports the presence of an in-
verted U-shape relationship between prefrontal dopami-
nergic activity and working memory (Cools and
D’Esposito, 2011). This inverted U-shaped relationship
may also explain the considerable inter-individual vari-
ation of quetiapine’s eﬀect on negative symptom ex-
pression in the present study. It seems that quetiapine,
seemingly by way of dopamine modulation, has either
beneﬁcial or detrimental eﬀects on negative symptoms
that can be predicted by a WM-related measure ; in this
case, frontoparietal connectivity.
Supporting our line of reasoning, previous studies
have suggested that WM-related proﬁles at baseline can
predetermine treatment response. For instance, the
Val108/158Met catechol-O-methyltransferase genotype,
Table 3. Comparison of features
Negative symptom improvers vs. non-improvers
Accuracy
(%)
Sensitivityb
(%)
Speciﬁcityb
(%)
Three components of interesta 78.57 75 83.33
Working memory
network components
78.57 62.5 100
Default mode network component 50.0 62.5 33.33
Right-lateralized working
memory network component
64.29 62.5 66.67
Bilateral working memory
network component
57.14 50 66.67
a The two working memory network components and the default mode network
component.
b True positives were those instances where improvers were classiﬁed accurately ; true
negatives were those instances where non-improvers were classiﬁed accurately.
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which has been associated with WM performance and
brain activity as well as risk for schizophrenia (Tan et al.
2007), predicted treatment outcome in schizophrenia
patients with less WM improvement (Weickert et al. 2004)
and poorer negative symptom outcomes (Bertolino et al.
2004, 2007) in Val homozygotes than Met allele carriers
after antipsychotic treatment. van Veelen et al. (2011)
found that pre-treatment WM prefrontal hyperactivity, as
measured with fMRI, predicted worsened general treat-
ment response after 10 wk. Furthermore, increases inWM
(Honey et al. 1999 ; Meisenzahl et al. 2006) and emotional
(Fahim et al. 2005 ; Stip et al. 2005) task-related prefrontal
activity after antipsychotic treatment have been found to
parallel improvements in negative symptoms.
We did not ﬁnd a direct relationship between the ex-
pression of negative symptoms and WM functional con-
nectivity at baseline. Classifying patients according to
baseline negative symptom scores demonstrated much
poorer accuracy (43%) than classifying based on treat-
ment response. Also, the stability of negative symptoms
could not be predicted based on WM-related network
activity at baseline. Groups deﬁned by magnitude
of change in negative symptom scores were poorly
classiﬁed with 57% accuracy. It therefore seems that
pre-treatment functional connectivity of WM-related
networks can predict the treatment response of nega-
tive symptoms but neither their temporal stability nor
baseline severity. Furthermore, age diﬀerences did not
seem to be driving the classiﬁcation results between the
negative symptom improvers and non-improvers.
However, these ﬁndings do not rule out that the afore-
mentioned factors and perhaps others such as history of
substance abuse, current non-antipsychotic medication
use and DUI, can interact with WM brain activity to
predict the course of negative symptom change. Any
possible interaction eﬀects do not undermine our ﬁnd-
ings but would be interesting avenues to pursue in future
studies.
An important limitation of this study is the relatively
small sample size. The present ﬁndings, therefore, need
to be replicated in a larger group of patients. A larger
sample size would have allowed us to adjust classiﬁer
parameters in order to improve classiﬁcation accuracy.
Nonetheless, we attained reasonable accuracy using a
relatively conservative kernel (linear) and an SVM clas-
siﬁer with default parameters. We attribute the signiﬁ-
cant results in such a small sample at least in part to the
strict inclusion criteria of our study, which ensured that
we studied a well-deﬁned and relatively homogenous
group of patients.
Finally, it is inherently diﬃcult to dissociate real drug
treatment eﬀects on negative symptoms from spon-
taneous ﬂuctuations in negative symptoms attributed to
the natural course of the disease. These factors can only
be disentangled by including an untreated control group
of schizophrenia patients, which for obvious ethical
reasons is not feasible.
In conclusion, we have demonstrated the applicability
of emerging methods in imaging psychiatry for the pre-
diction of treatment outcomes in schizophrenia.
Identifying neural activity patterns at baseline that pre-
dict treatment resistance will not only contribute to a
better understanding of the neural mechanisms involved
in symptom expression and in determining the course of
the disease, but ultimately may be used to tailor early and
individualized treatment. Such ends might be especially
important for the treatment of negative symptoms and
cognitive deﬁcits in light of their strong association with
functional outcome and the limited eﬀect current anti-
psychotic compounds have on these symptoms. Early
intervention tailored to treat cognitive deﬁcits and nega-
tive symptomsmight improve functional outcomes for all
high-risk individuals, with or without transition to psy-
chosis (Lin et al. 2011). There are currently no aids to help
clinicians tailor treatment to patients or those in at-risk
mental state. The current study will hopefully be one of
many studies to come, which aim to ﬁnd and reﬁne pre-
dictors of treatment response.
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